SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 61,072 put options on the company. This represents an increase of 65% compared to the average daily volume of 37,101 put options.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Price Performance

SELLAS Life Sciences Group stock traded up $0.73 during mid-day trading on Wednesday, hitting $11.78. The company’s stock had a trading volume of 5,527,704 shares, compared to its average volume of 8,273,316. The business has a 50 day moving average price of $11.01 and a 200-day moving average price of $7.24. SELLAS Life Sciences Group has a 12 month low of $1.39 and a 12 month high of $15.88. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -51.22 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in SELLAS Life Sciences Group by 86.6% in the 1st quarter. Bank of New York Mellon Corp now owns 478,366 shares of the company’s stock worth $2,023,000 after buying an additional 221,957 shares during the period. Dagco Inc. increased its stake in shares of SELLAS Life Sciences Group by 19.8% during the second quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after buying an additional 203,653 shares during the period. Fifth Third Bancorp bought a new stake in SELLAS Life Sciences Group in the first quarter valued at $253,000. World Investment Advisors purchased a new position in SELLAS Life Sciences Group during the 4th quarter valued at $166,000. Finally, Millington Financial Advisors LLC bought a new position in SELLAS Life Sciences Group in the 4th quarter worth $93,000. Institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.